Cantab Biopharmaceuticals Ltd is a drug development company focused on the development of “biosuperior” products. Based on Cambridge Science Park, Cantab is at the heart of the largest biotech cluster in Europe.
Cantab is using it’s extensive experience in biopharmaceutical discovery, process development and GMP manufacturing to expedite the development of biosuperiors from inception through clinical development.
Previously marketed, off-patent, biologics will be enhanced by the application of appropriate cutting-edge technologies in protein expression/engineering, process/manufacturing technology, protein conjugation, formulation and drug delivery.
Particular areas of drug characteristics that Cantab seek to improve upon are product presentation and stability, pharmacokinetics, pharmacodynamics, immunogenicity and drug delivery.
John has 13 years of operational experience in life science companies. He joined Abingworth in 2001 from Cantab Pharmaceuticals where he was Senior Vice President, Research. He had a strong role in business development and played a significant part in the in-licensing of new products and technologies to the firm. Prior to Cantab, he was at the Glaxo Institute for Molecular Biology in Geneva, Switzerland. From 1982 to 1988, he held research positions at the Institute of Child Health, the University of London, UK. John has a PhD in Immunology from the University of Glasgow. He has published more than 30 papers in peer-reviewed journals including Science. At Abingworth, John is involved with scientific evaluation of new and existing investments and works closely with UK universities and early-stage companies.
Finance & HR Manager at Cantab Biopharmaceuticals